- Home
- FRSX vs NCNA Comparison
FRSX vs NCNA Comparison
Compare FRSX & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FRSX | NCNA |
|---|---|---|
| Founded | N/A | 1997 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 5.7M |
| IPO Year | 2016 | 2017 |
Fundamental Metrics
Financial Performance| Metric | FRSX | NCNA |
|---|---|---|
| Price | $1.42 | $1.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 121.8K | 61.8K |
| Earning Date | 05-15-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.03 |
| 52 Week High | $3.00 | $10.00 |
Technical Indicators
Market Signals| Indicator | FRSX | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 39.06 | 34.07 |
| Support Level | $1.28 | $1.21 |
| Resistance Level | $1.46 | $2.27 |
| Average True Range (ATR) | 0.11 | 0.12 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 14.27 | 24.29 |
Price Performance
Historical ComparisonAbout FRSX Foresight Autonomous Holdings Ltd.
Foresight Autonomous Holdings Ltd is a technology company engaged in the development of 3D perception systems and cellular-based applications. The company designs, develops, and commercializes in-line-of-sight vision systems and beyond-line-of-sight accident prevention solutions through its subsidiaries. Its solutions are based on stereo vision, 3D perception, and V2X technologies, aimed at improving safety by enabling accurate obstacle detection and real-time alerts. The company targets multiple industries, including automotive, defense, agriculture, and heavy equipment.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.